Clinical Ageing Research Unit, Newcastle University, Campus for Ageing and Vitality, Newcastle upon Tyne, UK.
Bone Clinic, Freeman Hospital, Freeman Road, Newcastle upon Tyne, UK.
J Parkinsons Dis. 2017;7(4):669-675. doi: 10.3233/JPD-171122.
Previous cross-sectional studies have shown that Parkinson's disease (PD) patients have lower serum 25-hydroxy vitamin D (25(OH)D) concentrations than controls. Vitamin D deficiency was associated with increased disease severity and cognitive impairment in prevalent PD patients.
The aim of the study was to determine 25(OH)D in newly diagnosed PD and age-matched controls and to assess if there was an association with clinical outcomes (disease severity, cognition and falls) over the 36-month follow up period.
A prospective observational study of newly diagnosed PD patients in the North East of England with age-matched controls (PD, n = 145; control, n = 94). Serum 25(OH)D was assessed at baseline and 18 months. Participants underwent clinical assessment at baseline, 18 and 36 months. One hundred and ten participants with PD also took part in a prospective falls study.
Mean serum 25(OH)D concentrations were lower in PD than control participants at baseline (44.1±21.7 vs. 52.2±22.1 nmol/L, p < 0.05) and 18 months (44.2±23.6 vs. 55.7±28.8 nmol/L, p < 0.05). Baseline serum 25(OH)D concentration, age, motor score and dosage of dopaminergic medication were significant predictors of variance of motor severity at 36 months ((ΔR2 = 0.039, F = 6.6, p < 0.01). Serum 25(OH)D was not associated with cognition or falls during the follow up period.
Patients with incident PD had significantly lower serum 25(OH)D concentrations than age-matched controls, which may have implications in terms of bone health and fracture risk. There was a small but significant association between vitamin D status at baseline and disease motor severity at 36 months.
先前的横断面研究表明，帕金森病（PD）患者的血清 25-羟维生素 D（25（OH）D）浓度低于对照组。维生素 D 缺乏与现患 PD 患者的疾病严重程度和认知障碍增加有关。
本研究旨在确定新诊断的 PD 患者和年龄匹配的对照组中的 25（OH）D，并评估其在 36 个月随访期间与临床结局（疾病严重程度、认知和跌倒）的相关性。
一项在英格兰东北部进行的新诊断 PD 患者的前瞻性观察性研究，纳入了年龄匹配的对照组（PD 组，n=145；对照组，n=94）。在基线和 18 个月时评估血清 25（OH）D。参与者在基线、18 个月和 36 个月时接受临床评估。110 名 PD 患者还参加了一项前瞻性跌倒研究。
PD 组患者的血清 25（OH）D 浓度在基线时（44.1±21.7 与 52.2±22.1 nmol/L，p<0.05）和 18 个月时（44.2±23.6 与 55.7±28.8 nmol/L，p<0.05）均低于对照组。基线血清 25（OH）D 浓度、年龄、运动评分和多巴胺能药物剂量是 36 个月时运动严重程度变异的显著预测因素（ΔR2=0.039，F=6.6，p<0.01）。在随访期间，血清 25（OH）D 与认知或跌倒无关。
新发 PD 患者的血清 25（OH）D 浓度明显低于年龄匹配的对照组，这可能对骨骼健康和骨折风险产生影响。基线时维生素 D 状态与 36 个月时疾病运动严重程度之间存在较小但显著的关联。
